Search results
25 sie 2023 · Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No...
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ...
In patients with preexisting cardiovascular disease and...
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ...
30 wrz 2020 · The explanatory variables in the model were randomized treatment (semaglutide or comparator), baseline CV risk score (from the CV risk prediction model derived from the LEADER data as described above) and the interaction between treatment and CV risk score.
11 lis 2023 · In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the ...
6 kwi 2024 · Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target...
For participants without HF at baseline, the risk reduction for CV death was 29% in the semaglutide group (HR: 0.71; 95% CI: 0.53-0.93; P = 0.0154), with 83 events in the semaglutide group (rate 1.7 per 100 PY of follow-up) and 116 events in the placebo group (rate 2.5 per 100 PY of follow-up).
25 sie 2023 · In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF Clinica ….
Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) is a randomized, double-blind, parallel-group trial testing if semaglutide 2.4 mg subcutaneously once weekly is superior to placebo when added to standard of care for preventing major adverse cardiovascular events in patients with established CVD and ...
